Recent advances in preoperative management of esophageal adenocarcinoma.
Recent advances in preoperative management of esophageal adenocarcinoma.
复制标题
DOI：
10.12688/f1000research.10794.1
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Ajani JA
中科院分区：
文献类型：
--
作者：
Harada K;Mizrak Kaya D;Baba H;Ajani JA
Esophageal cancer is an aggressive malignancy with increasing incidence, and the prognosis of patients treated by surgery alone remains dismal. Preoperative treatment can modestly prolong overall survival. Preoperative chemotherapy or chemoradiation is the standard of care for resectable esophageal cancer (greater than clinical stage I and less than clinical stage IV). One of the challenges is to predict complete response in the surgical specimen from preoperative therapy and to avoid surgery in some patients but also predict ineffectiveness of preoperative therapy if the tumor is resistant and avoid such therapies altogether. In-depth understanding of the molecular biology could lead to personalized therapy, and in the future, clinical trials designed according to molecular features are expected. Here, we summarize preoperative treatment for esophageal adenocarcinoma and their potential.
